Dinitrochlorobenzene
In clinical developmentAlso known as 1-chloro-2,4-dinitrobenzene, dinitrochlorobenzene (2,4).
Recent clinical, regulatory, research and industry developments relating to this drug.
A human 3D immune competent full-thickness skin model mimicking dermal dendritic cell activation.
Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Frontiers in immunology1
- Blasius N1
- Buhl T1
- Engels U1
- Friedrich K1
- Hölken JM1
- Merkel M1
- Mewes KR1
- Teusch NE1
- Institute of Pharmaceutical Biology and Biotechnology1
- University Medical Center Göttingen1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials